Member Info for Buyinthedip

Dave thanks so much for this insight honestly what we would do without this I do not know

Thorn - simple question as you seem to like raising them so much

On the information and evidence you have seen to date on Avacta would you give your most closest and dearest in your life straight Dox or AV6000 should the treatment be needed and why…

What is realistic timescales to expect this to land

FDA validation has to be a value driver in the absence of a LD surely

What are you talking about phase 1 to healthy patients for safety what utter nonsense

“Your only supposed to blow the doors off”

Just you wait Thorno and the wannabe I told you so brigade

McGurk expand your comments you lemon giving it out without context honestly FUD off !

You post the same thing over and over again about management concerns.

What could Avacta get better now will only be determined at the end result. If it is as good as talked then they are in actual fact playing an absolute blinder right now.

Every nuance can be examined and analysed

The most important single fact is in June at the AGM it was said peer reviewed data mid 2024

That changed and Avacta brought their own deadline in of Q4 2023.

This company and Sir Al don’t do that for no reason at all, something changed to warrant the action

I expected more from yesterday and it is Consilium not Sir Al to review here for me and hope there is a underlying process ongoing thats meant this release is tick box for something bigger in the short term

Otherwise why now and not wait for the data to have matured in P2 with better profiled patients showing better efficacy data for a media splash…

How much does it work worth sell make cost convert save for?

People are losing far too much sleep over a stock commentator!

There are commentators for everything in life, football, politics it is perfectly normal

Martin Lewis is a commentator of the people for finance apparently...

He is also now worth £123 millions branding out his points of view and selling all his data to Money Supermarket

It is your money, your decisions and if you are the numpty that follows one persons insight it is only you that is a numpty not him when/if it goes wrong.

I value his thoughts as I do many others on Twitter

GLA to all those sensible screwed on heads remaining calm.

It is down to whether RNS and data information holds enough time and therefore value in the community on waiting for potentially more data on the Xmas run up week when lots of parties and distractions are around…

If you don’t think it does then we are already in THE week.

The data is written as they go so it is only C7 inclusion that is holding this IMO

It really demonstrates that the toxicity reduction alone versus only equal to even less efficacy (but able to deliver more over lifetime) changes standard of care overnight and widens the existing market tremendously. The CoS / criteria really is not needing to be as high to be an outstanding success for patients and SH’s alike

To be fair more were on this BB talking up a license deal yesterday with absolutely no reasoning whatsoever. I do feel Twitter regulars get somewhat of an unfair brush by some on here. Whilst the magic calculator estimates are rush of blood enablers, much of my learning of BioTech sales, valuations, & overall market precedence's come from some of those very people. On here too often there is pointless back and forth lacking using any evidence based arguments. I pardon to the few on here who do (BuenaV / Tim / Jive etc)

Sheppy better than Sujood & Hurst100 combined

*over 30p now :-)

Isn't there a weigh up between 30% effectiveness with those horrible side effects (and noted deaths in the trial) to hugely upscaled therapeutic benefits of an existing treatment that may be able to be delivered much more regularly? On top of that to a much wider / vulnerable patient profile without any / minimal side effects. Surely this is exactly where Consilium slot in to earn their crust!

With all the media coverage for a "turning point" in Alzheimer's treatment that "only" gives stats of circa 30% effectiveness, it does make you wonder what will happen even before certain inflection points if sentimental trading takes off with some solid media coverage of Avacta... chemo without side effects...

I joined in the LFT build up to ATH's at that time probably £2 and then re bought in the dips as 6k took momentum to bring the average down to under £1.40 now - from seeing other posts, it seems to correlate with quite a few other people!

I bought this stock before my little one was born. She is talking, walking and making more on her JISA than I have in this stock :-( when is the biblical move happening, I believe in everything I see - when will everyone else?!

As always it's DYOR but what's existing investors overview of this in the coming months on SP more ATH's to come? Newly jumped on board ... Financials look good following and the potential seems huge as well as client potential ...